Amgen Stock Climbs 4.34% Following Positive Trial News
📈 Amgen stock rose 4.34% to close at $410.24 on September 23, 2026.
🧬 The experimental drug dazodalibep met its primary late-stage trial goal for Sjogren disease.
📈 Jefferies raised its price target for Amgen to $410.00 following the positive trial data.
Bullish Signals
- Amgen stock gained 4.34% on September 23, 2026, closing at $410.24 after dazodalibep met its primary late-stage trial goal for Sjogren disease.
- Analyst firm Jefferies raised its price target to $410.00 following the successful trial results for the experimental treatment.
Full Analysis
Amgen's stock price increased by 4.34% on September 23, 2026, closing at $410.24 on the Nasdaq. This upward movement occurred despite a broader decline in the Nasdaq Composite, which fell 1.13% to close at 26,936.04 points.
The rally was primarily driven by positive late-stage clinical trial results for dazodalibep, an experimental treatment for Sjogren disease. The drug successfully met its primary endpoint in the trial, validating its efficacy and advancing its development profile toward potential regulatory approval.
